Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis: a Multinational, Randomised, Open Label, Phase III Trial - The iCaD Study

NCT05947669 is registered in ClinicalTrials.gov with Odense University Hospital as lead sponsor.

NCT NCT05947669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis: a Multinational, Randomised, Open Label, Phase III Trial - The iCaD Study
Lead sponsor
Odense University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
August 22, 2023
Completion date
September 30, 2028
Enrollment
195 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colitis